Spotted a factual error — a wrong number, date, or fact? Tell us and we will check the source.
1. At a Glance
Neogen Chemicals is that chemical stock which investors treat like a Tesla cousin — because hey, it says “lithium” somewhere in the presentation. Market cap ₹3,774 Cr, sales just ₹784 Cr, profits ₹40 Cr… and a valuation of 93x P/E. Basically, this is the Starbucks latte of stocks: overpriced, fancy-sounding, but still just coffee with foam.
2. Introduction
Founded in 1991, back when Doordarshan ruled TV, Neogen quietly grew into a niche specialty chemical player. It imports lithium salts, cooks up 246 different compounds, and sells to everyone from pharma giants (Sun Pharma, Divis) to agro-chemical honchos.
Its claim to fame?
Largest importer of lithium carbonate & hydroxide in India.
First Indian co. with Mitsubishi JV-backed lithium electrolyte tech.
R&D-heavy with 93 scientists (11 PhDs — more than some IIT faculties).
Sounds dreamy, right? Except, profits are flatter than a dosa. Capex is guzzling cash, ROE is 5.5%, and promoter holding has slipped from 60% to 51%. Yet, Dalal Street chants: “Lithium hai toh future hai.”
3. Business Model (WTF Do They Even Do?)
Neogen runs two segments:
Organic Chemicals (84% of revenue): bromine compounds, intermediates, contract manufacturing for pharma/agro.
Inorganic Chemicals (16%): lithium-based inorganics for pharma, batteries, construction.
Applications? From medicines to semiconductors, crop protection to flavours. In short: “agar molecule hai, hum bana denge.”
Add-ons:
BuLi Chem acquisition (FY24) → Only non-China maker of organolithium outside US/EU.
Neogen Ionics (subsidiary) → Making lithium electrolytes for EV batteries.
So, the pitch is: “From pills to EVs, we got you covered.” The reality: still small fry compared to Deepak Nitrite or Navin Fluorine.
